protein tyrosine phosphatase SHP2 inhibitor (Case Western Reserve University/Tianjin Institute of Pharmaceutical Research/Tianjin Medical University/University of California San Francisco)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Nameprotein tyrosine phosphatase SHP2 inhibitor (Case Western Reserve University/Tianjin Institute of Pharmaceutical Research/Tianjin Medical University/University of California San Francisco)
Drug Alias Namecryptotanshinone(-)-cryptotanshinone
ClassificationSmall moleculesNatural product/Extract
Mechanisms of ActionSrc homology phosphotyrosyl phosphatase 2 inhibitors
TargetsSrc homology phosphotyrosyl phosphatase 2
Therapy Area/IndicationsSolid tumoursNoonan SyndromeLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesTianjin Pharmaceutical Research Institute Of The State Drug Administration
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of California San FranciscoCase Western Reserve UniversityTianjin Medical University +[4] 
Active IndicationsN/A
Inactive IndicationsSolid tumoursNoonan SyndromeLeukemia

Other Information

ATC CodeN/A
Related LinksN/A